Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
Updated by a group of distinguished regulatory experts, this new edition is a must-have handbook for regulatory professionals at all levels.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 17 January 2018 | By Zachary Brennan
The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) announced Wednesday that it has met its three strategic goals from 2016 and 2017 and it has outlined three more for 2018 to 2022.
Looking ahead to these next three years, CDRH Director Jeff Shuren pointed to three priorities: Better engage the center’s employees and decrease turnover rates, streamline and modernize at least 80% of the center’s processes, and establish new work with a more varied group of stakeholders and companies.
By 31 December 2020, Shuren said CDRH aims to have more than 50% of manufacturers of novel technologies (i.e., devices subject to an original Premarket Approval (PMA) application, panel-track supplements, De Novo classification requests, Humanitarian Device Exemption (HDE), or a premarket notification [510(k)] that is under the breakthrough devices program) bring their devices to the US first or in parallel with other major markets.
"Over the past two years, we have explored, piloted, and developed implementation plans to combine our Office of Compliance, Office of Surveillance and Biometrics, and Office of Device Evaluation into a single 'super office.' This re-organization, which will also include the Office of In Vitro Diagnostics and Radiological Health (OIR), will help us improve information sharing, decision making, and work efficiency by instituting a TPLC1 approach to many of our core activities, similar to how OIR operates today," the report on strategic priorities said.
The strategic priorities also notes collaborative forums for next generation sequencing tests, benefits offered by the Unique Device Identification (UDI) system, a public-private forum established to create a competitive and transparent marketplace around device quality, as part of CDRH’s Case for Quality initiative, and progress made with the National Evaluation System for health Technology.
2018-2020 STRATEGIC PRIORITIES Center for Devices and Radiological Health
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH) 2016-2017 STRATEGIC PRIORITIES – ACCOMPLISHMENTS
Tags: novel devices, UDI, NGS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.